Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center

PURPOSE: The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of utilization, tolerance, and outcomes with pomalid...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JCO Glob Oncol
Asıl Yazarlar: Bondili, Suresh Kumar, Bagal, Bhausaheb, Zawar, Abhinav, Ventrapati, Pradeep, Thorat, Jayashree, Gokarn, Anant, Punatar, Sachin, Nayak, Lingaraj, Bonda, Avinash, Jain, Hashmukh, Sengar, Manju, Khattry, Navin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wolters Kluwer Health 2021
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8081531/
https://ncbi.nlm.nih.gov/pubmed/33689483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/GO.20.00228
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller